Transforming medicine and changing lives


February 17, 2021

Selecta and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR in Gene Therapy

Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR™ to mitigate formation of antibodies to AAV capsids used in gene therapy. the news

We are on a never-ending quest to advance genetic technology

and life-saving AAV gene therapy

In 1984, Dr. Jude Samulski, one of AskBio’s visionary founders, asked if a virus could be used to erase genetic disease. Discovering the answer cleared the path for historic advances in genetic medicine, and AskBio is leading the way.

Learn about AskBio »

gene therapy

Revolutionizing gene therapy

Cures for life-altering diseases depend on new technology to lower the cost of treatment and increase supply for every patient who needs it.

Explore our technology »

Clinical Pipeline

Changing lives

Our clinical pipeline is the direct result of listening to patients, their families, their care teams and disease-advocacy organizations.

Discover our pipeline »

Putting patient care first

The voices of patients drive everything we do. They propel our research and the urgent need to find cures.

For Patients »

Work with us

Advancing research

Today’s genetic discoveries are some of the most awe-inspiring advances in medical history. We welcome collaboration with innovative minds in genetic R&D.

Building careers

Help transform the face of healthcare with life-changing gene therapy. Every life enriched by our scientific advancements is a result of someone like you.


BioProcess International U.S. West 2021

Mar 29

Mar 31

Andy Holt, EVP, Commercial Development, will present “Platform Development in AAV Manufacturing: Cost & Timeline Impact on Clinical Development” on March 30 (1:15-1:35pm PDT) at the BioProcess International U.S. West 2021 conference.